←Anxiety Disorders
Study register · detail Meta-Analyse · Anxiety Disorders · 2024

Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis.

Han et al. ·Psychiatry research Impact 4.1
Clear benefit GRADE High 43 citations
Samplek = 8 Studien
n = 316 Pat.
Durationunclear
ControlPlacebo
EndpointAnxiety intensity
Blindingunklar
DesignMeta-Analyse
Cannabinoidcbd
Key finding

CBD showed a significant effect on anxiety disorders with a large effect size (Hedges' g = -0,92, 95% CI -1,80 to -0,04).

Summary

Systematic review + meta-analysis of CBD in anxiety disorders (GAD, SAD, PTSD); k=8 RCTs, n=316 participants. Significant effect of CBD on anxiety with large effect size (Hedges' g=-0.92, 95% CI -1.80 to -0.04, p<0.05). Limitation: limited clinical sample size.

P
PopulationAdults with anxiety disorders (GAD, SAD, PTSD), pooled n=316
I
InterventionCannabidiol (CBD), various dosages and forms of administration
C
ControlPlacebo
O
OutcomeSignificant anxiety reduction with CBD (Hedges' g = -0,92, 95% CI -1,80 to -0,04)
Confidence in the evidence
High

The highest of four GRADE levels, the effect estimate is very reliable.

Quality profile
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
Authors
Han K, Wang JY, Wang PY, Peng YC
DOI 10.1016/j.psychres.2024.116049↗
Design: Meta-Analyse
Share
Abstract
Cannabidiol (CBD), as one of the phytocannabinoids, has a wide range of therapeutic properties for various neuropsychiatric disorders due to central nervous system effects. These therapeutic properties demonstrated by preclinical and clinical studies encompass more than just anticonvulsant, anti-arthritic, analgesic, anti-inflammatory, antioxidant, antitumor, antiemetic, antipsychotic and neuroprotective effects. It has been hypothesized that CBD holds potential in the treatment of various neuropsychiatric and anxiety disorders. Thus, PRISMA was used as a guide for our systematic review. Eight of the 1550 articles screened in June 2023 were eligible for meta-analysis. Based on the 316 participants included in these eight articles, this meta-analysis revealed a substantial significant impact of CBD on anxiety with a considerable effect size (Hedges' g = -0.92, 95% CI -1.80 to -0.04). In addition, this meta-analysis focuses on the efficacy of CBD in treating anxiety disorders such as generalized anxiety disorder (GAD), social anxiety disorder (SAD), and post-traumatic stress disorder (PTSD). However, caution should be exercised in interpreting our findings due to the limited size of the clinical sample, and additional trials ought to be carried out if deemed necessary.
Indication
Further studies on Anxiety Disorders
All studies →
S Whiting et al. · 2015 · JAMA
2103 citations
Cannabinoids for Medical Use
Mixed

Umfassende SR über 79 RCTs (n=6.462) zu medizinischem Cannabis; KEINE ausreichende Evidenz für Angststörungen als primäres Outcome — moderate Evidenz nur für Schmerz und MS-Spastik, Angst nur als sekundäres/exploratives Outcome in einigen Studien.

10.1001/jama.2015.6358 View study →
A Kedzior et al. · 2014 · BMC psychiatry
299 citations
A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies.
Clear benefit Meta-Analyse

Meta-Analyse über k=31 Studien (n≈112.000) zur Assoziation zwischen Angststörungen und Cannabis-Konsum. Kleine positive Assoziation: Angst↔Cannabis-Konsum OR=1.24 (95% CI: 1.06-1.45, p=0.006), Angst↔Cannabis Use Disorder OR=1.68 (95% CI: 1.23-2.31, p=0.001). Prospektive Subgruppe (k=5): Baseline-Cannabis-Konsum prädiziert Follow-up-Angst OR=1.28 (95% CI: 1.06-1.54, p=0.01). Adjustiert für Confounder.

10.1186/1471-244x-14-136 View study →
A Roberts et al. · 2025 · Psychiatry research
3 citations
Medicinal cannabis in the management of anxiety disorders: A systematic review.
Mixed Systematic Review

Systematische Review zu medizinischem Cannabis bei Angststörungen; k=57 Studien (40% Kohorten, 30% RCTs, 18% Querschnitt, 12% qualitative Designs). Unter den 13 hochwertigsten Studien zeigten 70% (n=9) positive Verbesserungen bei GAD, SAD und PTBS; 30% (n=4) negative Ergebnisse bei OCD, Trichotillomanie, Prüfungsangst und SAD. Über 90% aller Studien berichteten positive Outcomes für CBD- und THC-basiertes Cannabis. MASTER-Score: 62,9/100 (hohes Bias-Risiko durch unzureichendes Reporting). 53% (n=30) der Studien omittierten oder verwendeten selbstberichtete Daten zu Form/Dosierung.

10.1016/j.psychres.2025.116552 View study →

The impediment to action advances action. — Marcus Aurelius